JAMP Pharma Group receives Health Canada approval for PrJAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes
The JAMP Pharma Group has received authorization to market Sitagliptin, offering a more affordable alternative to the reference product Januvia® (marketed by...
Source: newswire.ca